Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

Dai Chihara, Lucia Masarova, Kate J. Newberry, Hoyoung Maeng, Farhad Ravandi, Guillermo Garcia-Manero, Alessandra Ferrajoli, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Lenalidomide, with or without prednisone, is an active therapy for patients with myelofibrosis (MF). We provide an update of a phase II study of lenalidomide plus prednisone in patients with MF, after median follow up of 9 years. Forty patients were enrolled in the study and all patients were evaluable for response. Response to the treatment was reevaluated using IWG response criteria published in 2013: quality of response improved over time and overall response rate was 35%. Response in splenomegaly was seen in 39% of patients and anemia response in 32%. The median time to treatment failure (TTF) in all patients was 8.2 months and the median duration of response was 34.6 months. Response was highly durable in some patients: six patients (15%) had TTF for more than 60 months (5 years) and three patients are still on the treatment beyond 109 months (9 years). Complete and partial responses were seen in one and five patients, respectively, but achieving deeper response was not necessary for the response to be durable. New clinical studies are needed to explore safe and well tolerated lenalidomide-based combination strategies for patients with MF.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalLeukemia Research
Volume48
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Keywords

  • Anemia
  • Complete response
  • Lenalidomide
  • Myelofibrosis
  • Prednisone
  • Splenomegaly

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis'. Together they form a unique fingerprint.

  • Cite this

    Chihara, D., Masarova, L., Newberry, K. J., Maeng, H., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Cortes, J., Kantarjian, H., & Verstovsek, S. (2016). Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia Research, 48, 1-5. https://doi.org/10.1016/j.leukres.2016.06.007